Table 1 Clinicopathological characteristics of patients with sarcoma treated with apatinib
From: Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety
Characteristic | Value |
|---|---|
Age | |
Mean | 42.16 yr |
Range | 11–83 yr |
Distribution | |
= <42 | 31(48.4%) |
>42 | 33(51.6%) |
Sex | |
Male | 33(51.6%) |
Female | 31(48.4%) |
ECOG performance-status score | |
0 | 2(3.1%) |
1 | 27(42.2% |
2 | 33(51.6%) |
3 | 2(3.1%) |
Tumor type-no (%) | |
Bone sarcomas | 22(34.4%) |
Osteosarcoma | 11(17.3%) |
Chondrosarcoma | 2(3.1%) |
PNET/EWS | 7(10.9%) |
Chordoma | 2(3.1%) |
Soft tissue sarcomas | 42(65.6%) |
UPS | 6(9.4%) |
Synovial sarcoma | 6(9.4%) |
MPNST | 7(10.9%) |
LMS | 5(7.8%) |
RMS | 6(9.4%) |
Fibrosarcoma | 5(7.8%) |
Other sarcoma | 7(10.9%) |
Metastasis site | |
Lung | 42(65.7%) |
Lung and other sites | 15(23.4%) |
Nonlung metastasis | 7(10.9%) |
